NEW YORK (GenomeWeb) – Sophia Genetics, a developer of bioinformatics for analyzing genetic test data, today said that it has raised $13.75 million in a Series B financing round.
The Lausanne, Switzerland-based company offers a software as a service called dropGen, which provides bioinformatic analyis, the validation and quality control process, and the presentation of genetic test results to clinicians while protecting patient DNA sequence data through safe storage and banking, it said.
The financing round was led by Invoke Capital, Swisscom, and Endeavour Vision.
As part of the investment, Sophia will gain access to Genalys, a portfolio company of Invoke Capital that is applying big data approaches to genomic information.
"This new funding will allow us to move faster into European markets," Sophia Genetics CEO Jurgi Camblong said in a statement. "Invoke Capital, in particular, provides a degree of expertise in data security in cloud and in scalability that will strengthen our genetic sequencing data banking offering immediately."